Results 131 to 140 of about 284,051 (203)

Diagnostic and Therapeutic Challenges of Homozygous and Severe Heterozygous Familial Hypercholesterolemia from Clinical Aspect-A Single-Center Study. [PDF]

J Clin Med
Nádró B, Kaluha J, Lőrincz H, Varga É, Balogh I, Harangi M.   +5 more
europepmc   +1 more source

Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia. [PDF]

J Clin Med, 2021
Peterson AL, Bang M, Block RC, Wong ND, Karalis DG.   +4 more
europepmc   +1 more source

Real-World Experience from Türkiye: Genetic and Therapeutic Insights in Pediatric Heterozygous Familial Hypercholesterolemia [PDF]

J Clin Res Pediatr Endocrinol
Yazıcı H, Er E, Erdem F, Yüksel Yanbolu A, Mammadova S, Alpdoğan S, Yoldaş Çelik M, Atik Altınok Y, Canda E, Aykut A, Akın H, Kalkan Uçar S, Çoker M.   +12 more
europepmc   +1 more source

Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). [PDF]

BMC Med, 2023
Chai M, He Y, Zhao W, Han X, Zhao G, Ma X, Qiao P, Shi D, Liu Y, Han W, An P, Li H, Yan S, Ma Q, Deng H, Qian L, Zhou Y, CREDIT-2 investigators.   +17 more
europepmc   +1 more source

Statins for children with familial hypercholesterolemia

, 2019
Background: Familial hypercholesterolemia is one of the most common inherited metabolic diseases and is an autosomal dominant disorder meaning heterozygotes, or carriers, are affected. Those who are homozygous have severe disease.
Vuorio, A., Humphries, S.E., Kovanen, P.T., Drogari, E., Tonstad, S., Wiegman, A., Kuoppala, J., Ramaswami, U.   +7 more
core  

Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins. [PDF]

J Clin Med, 2021
Marco-Benedí V, Laclaustra M, Sánchez-Hernández RM, Ortega-Martínez de Victoria E, Pedro-Botet J, Puzo J, Civeira F.   +6 more
europepmc   +1 more source

Oral Porphyromonas gingivalis and Fusobacterium nucleatum Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia. [PDF]

Biomedicines, 2022
Curia MC, Pignatelli P, D'Antonio DL, D'Ardes D, Olmastroni E, Scorpiglione L, Cipollone F, Catapano AL, Piattelli A, Bucci M, Magni P.   +10 more
europepmc   +1 more source

Glucose metabolism in heterozygous familial hypercholesterolemia with a founder effect and a high diabetes prevalence: a cross-sectional study. [PDF]

Cardiovasc Diabetol
González-Lleó AM, Brito-Casillas Y, Martín-Santana V, Gil-Quintana Y, Tugores A, Scicali R, Riaño M, Hernández-Baraza L, Jiménez-Monzón R, Girona J, Di Giacomo Barbagallo F, Masana L, Boronat M, Wägner AM, Sánchez-Hernández RM.   +14 more
europepmc   +1 more source

Myocardial fibrosis assessed by magnetic resonance imaging in asymptomatic heterozygous familial hypercholesterolemia: the cholcoeur study. [PDF]

EBioMedicine, 2021
Gallo A, Giral P, Rosenbaum D, Mattina A, Kilinc A, Giron A, Bouazizi K, Gueda Moussa M, Salem JE, Carrié A, Carreau V, Béliard S, Bittar R, Cluzel P, Bruckert E, Redheuil A, Kachenoura N.   +16 more
europepmc   +1 more source

Apparent Nonresponse to PCSK9 Inhibition in a Patient With Heterozygous Familial Hypercholesterolemia Due to PCSK9 Gene Duplication. [PDF]

JACC Case Rep
Pindwarawala M, Bose S, Brunham LR.
europepmc   +1 more source